ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,809.74
0.61%
Dow Jones
43,840.91
1.39%
Gold vs US Dollar
2,857.93
0.00%
Brent Oil
73.045
0.00%
Bitcoin
85,068.70
-1.12%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Pharma Equity Group A/s (0REU)

  7. Pharma Equity Group A/s (0REU) News

Pharma Equity Group A/s (0REU)

Pharma Equity Group A/s
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0REU
DateTimeSourceHeadlineSymbolCompany
28/02/202512:19UK Regulatory2025 Financial CalendarLSE:0REUPharma Equity Group A/s
28/02/202511:56UK RegulatoryChange of executive management and organizational change in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
14/01/202509:06UK RegulatoryPharma Equity Group 2025 Financial CalendarLSE:0REUPharma Equity Group A/s
13/12/202411:21UK RegulatoryThe Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.LSE:0REUPharma Equity Group A/s
29/11/202406:45UK RegulatoryMartin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
15/11/202407:32UK RegulatoryConsolidated Interim report 1 January – 30 September 2024LSE:0REUPharma Equity Group A/s
23/10/202408:28UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.LSE:0REUPharma Equity Group A/s
14/10/202406:17UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
14/10/202405:59UK RegulatoryManagers’ transactions LSE:0REUPharma Equity Group A/s
11/10/202406:37UK RegulatoryPharma Equity Group announces successful completion of directed issue of new sharesLSE:0REUPharma Equity Group A/s
04/10/202411:52UK RegulatoryPharma Equity Group announces issuance of new shares in a direct issueLSE:0REUPharma Equity Group A/s
04/10/202407:01UK RegulatoryRegistration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rightsLSE:0REUPharma Equity Group A/s
16/08/202406:52UK RegulatoryConsolidated Interim Report 1 January – 30 June 2024LSE:0REUPharma Equity Group A/s
16/07/202408:09UK RegulatoryThe Board of Directors' decision to issue convertible loansLSE:0REUPharma Equity Group A/s
15/07/202414:22UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
15/07/202414:12UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
03/06/202414:17UK RegulatoryResults of extraordinary general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/05/202410:35UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
16/05/202405:27UK RegulatoryConsolidated interim report 1 January – 31 March 2024LSE:0REUPharma Equity Group A/s
08/05/202413:16UK RegulatoryExploration of options regarding a directed capital increase at market price in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
08/05/202408:20UK RegulatoryNotice convening the extraordinary general meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
23/04/202409:45UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/04/202415:29UK RegulatoryPassing of the General Meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
10/04/202412:21UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
05/04/202409:22UK RegulatoryPharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.LSE:0REUPharma Equity Group A/s
25/03/202412:06UK RegulatoryNotice convening the annual general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
22/03/202408:00UK RegulatoryPharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009LSE:0REUPharma Equity Group A/s
21/03/202415:32UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
20/03/202407:58UK RegulatoryPharma Equity Group A/S - Annual Report 2023LSE:0REUPharma Equity Group A/s
05/03/202409:11UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).LSE:0REUPharma Equity Group A/s
 Showing the most relevant articles for your search:LSE:0REU

Your Recent History

COIN
BSXBTC
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads